Ohara Pharmaceutical Co., Ltd.
Records under this name other than the patents Ohara Pharmaceutical Co., Ltd. holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned. None of them is counted in the 2 patents it holds.
Showing 1 to 6 of 6 · Back to Ohara Pharmaceutical Co., Ltd.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 11,173,174 | DNMT inhibitor as solid tumor therapeutic drug Lapsed on the fee record Ended Nov 16, 2025 · From the USPTO record | Lapsed on the fee record | Ended Nov 16, 2025 | From the USPTO record |
| US 9,670,238 | 5′-dibenzyl phosphates of 5-azacytidine or 2′-deoxy-5-azacytidine Lapsed on the fee record Ended Jun 6, 2025 · From the USPTO record | Lapsed on the fee record | Ended Jun 6, 2025 | From the USPTO record |
| US 8,338,414 | Immunosuppressive agent and anti-tumor agent comprising heterocyclic compound as active ingredient Lapsed on the fee record Ended Dec 25, 2024 · From the USPTO record | Lapsed on the fee record | Ended Dec 25, 2024 | From the USPTO record |
| US 10,227,374 | Silyl etherified derivatives of 5-azacytidines in carbohydrate moiety Lapsed on the fee record Ended Mar 12, 2023 · From the USPTO record | Lapsed on the fee record | Ended Mar 12, 2023 | From the USPTO record |
| US 7,071,189 | Heterocyclic compound and antitumor agent containing the same as active ingredient Term ended Term ended Apr 26, 2022 · From the USPTO record | Term ended | Term ended Apr 26, 2022 | From the USPTO record |
| US 8,227,463 | Amorphous body composed of heterocyclic compound, solid dispersion and pharmaceutical preparation each comprising the same, and process for production of the same Lapsed on the fee record Ended Jul 24, 2020 · From the USPTO record | Lapsed on the fee record | Ended Jul 24, 2020 | From the USPTO record |